Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study

PURPOSE: Adavosertib is a small-molecule, ATP-competitive inhibitor of Wee1 kinase. Molecularly targeted oncology agents have the potential to increase the risk of cardiovascular events, including prolongation of QT interval and associated cardiac arrhythmias. This study investigated the effect of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Någård, Mats, Ah-See, Mei-Lin, Strauss, James, Wise-Draper, Trisha, Safran, Howard P., Nadeau, Laura, Edenfield, William J., Lewis, Lionel D., Rekić, Dinko, Dota, Corina, Ottesen, Lone H., Li, Yan, Mugundu, Ganesh M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326086/
https://www.ncbi.nlm.nih.gov/pubmed/37368100
http://dx.doi.org/10.1007/s00280-023-04555-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326086/
https://www.ncbi.nlm.nih.gov/pubmed/37368100
http://dx.doi.org/10.1007/s00280-023-04555-2

Ejemplares similares